Children's rare disease cohorts: an integrative research and clinical genomics initiative

Shira Rockowitz1,2,3, Nicholas LeCompte1,2,3, Mary Carmack1,2,3

  • 1Computational Health Informatics Program, Boston Children's Hospital, Boston, MA 02115 USA.

NPJ Genomic Medicine
|July 14, 2020
PubMed

Insights

Creating a unified genomics learning system (GLS) harmonized pediatric rare disease data. This approach streamlines sequencing and integrates clinical data for improved research and diagnostics.

Area of Science:

  • Genomics
  • Bioinformatics
  • Rare Diseases

Background:

  • Genomic data is often fragmented across different research protocols and clinical settings.
  • Harmonizing genomic data, especially for pediatric rare diseases, presents significant challenges for research institutions.
  • Integrating diverse data types and stakeholder needs is crucial for effective genomics workflows.

Purpose of the Study:

  • To present the outcomes of the Children's Rare Disease Cohorts (CRDC) initiative's first phase at Boston Children's Hospital.
  • To establish a unified genomics learning system (GLS) for pediatric rare disease research and clinical practice.
  • To create a broadly sharable, harmonized database of genomic and phenotypic data.

Main Methods:

  • Developed a genomics learning system (GLS) integrating exome and genome sequencing data.
  • Created a relational database for centralized storage and analysis of 8516 exomes and 112 genomes.
  • Utilized manual annotation and natural language processing (NLP) for phenotype extraction from clinical records.
  • Implemented machine learning algorithms for automated variant classification and prioritization.

Main Results:

  • Successfully created a sharable database of 2441 exomes from 15 pediatric rare disease cohorts.
  • The GLS integrates genomic, phenotypic, and clinical data, supporting 8516 exomes and 112 genomes.
  • Automated variant classification and NLP-based phenotype extraction are integrated within the GLS.
  • The platform demonstrates extensibility for future data and analytical system integration.

Conclusions:

  • The Children's Rare Disease Cohorts initiative successfully established a harmonized genomics learning system.
  • This unified approach facilitates centralized data storage, analysis, and sharing for pediatric rare diseases.
  • The GLS provides a robust and extensible platform for advancing genomic research and clinical applications.

Related Concept Videos

Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
15.1K
Genomics02:02

Genomics

Genomics is the science of genomes: it is the study of all the genetic material of an organism. In humans, the genome consists of information carried in 23 pairs of chromosomes in the nucleus, as well as mitochondrial DNA. In genomics, both coding and non-coding DNA is sequenced and analyzed. Genomics allows a better understanding of all living things, their evolution, and their diversity. It has a myriad of uses: for example, to build phylogenetic trees, to improve productivity and...
39.3K
Human Genetics01:28

Human Genetics

Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
1.3K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.4K
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K